Immutep Ltd ADR YP1A
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.30
- Day Range
- $2.32–2.32
- 52-Week Range
- $1.36–4.32
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $275.81 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 41
- Website
- https://www.immutep.com
Comparables
Valuation
|
Metric
|
YP1A
|
02315
|
IMU
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.87 | 3.82 | 2.91 |
Price/Sales | — | 4.17 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
YP1A
02315
IMU
Financial Strength
|
Metric
|
YP1A
|
02315
|
IMU
|
|---|---|---|---|
Quick Ratio | 16.76 | 1.02 | 5.46 |
Current Ratio | 17.24 | 1.30 | 5.73 |
Interest Coverage | −2,661.73 | −5.27 | — |
Quick Ratio
YP1A
02315
IMU
Profitability
|
Metric
|
YP1A
|
02315
|
IMU
|
|---|---|---|---|
Return on Assets (Normalized) | −34.01% | −13.53% | −41.83% |
Return on Equity (Normalized) | −36.95% | −37.28% | −45.23% |
Return on Invested Capital (Normalized) | −38.89% | −20.22% | −47.05% |
Return on Assets
YP1A
02315
IMU
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xmrsyvvbsz | Rzky | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rtglrcwp | Gzblfl | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rvgfbrcd | Fcfmd | $97.8 Bil | |
MRNA
| Moderna Inc | Jmhqxrmf | Zmzbn | $41.3 Bil | |
ARGX
| argenx SE ADR | Qnywdhns | Grrpg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jcsypwn | Jpcz | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wbmrgddb | Gtjypgs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nbjdqxqh | Pryyg | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ftfyxhxrp | Swxjz | $12.5 Bil | |
INCY
| Incyte Corp | Zmftqfj | Jjynv | $11.6 Bil |